Deepak Raja, MD
Ophthalmology · Orlando, FLNPI 1215143771
Payments from drug & device makers
Across 424 payments — averaging $145.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$19K
- Sun Pharmaceutical Industries Inc.$14K
- Novartis$9K
- Shire North American Group Inc$4K
- Dompe US, Inc.$3K
- Kala Pharmaceuticals, Inc.$2K
- plus $11K from 25 others
What the payments were for
- Consulting fees$6,18810%
- Speaking & faculty fees$35,87758%
- Travel & lodging$7,44312%
- Food & beverage$12,14920%
- Education$280%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 57 | $19,095 |
| Sun Pharmaceutical Industries Inc. | 52 | $13,596 |
| Novartis | 20 | $9,377 |
| Shire North American Group Inc | 11 | $3,955 |
| Dompe US, Inc. | 25 | $3,324 |
| Kala Pharmaceuticals, Inc. | 16 | $1,809 |
| Carl Zeiss Meditec USA, Inc. | 3 | $1,642 |
| Biotissue Holdings Inc. | 16 | $1,642 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $1,597 |
| AbbVie(2 entities) | 39 | $1,131 |
| Alcon | 22 | $856 |
| Bausch & Lomb Americas Inc. | 25 | $731 |
| Oyster Point Pharma, Inc. | 22 | $603 |
| Harrow Eye, LLC | 33 | $597 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $476 |
| Sight Sciences, Inc. | 10 | $315 |
| Tarsus Pharmaceuticals, Inc. | 5 | $288 |
| Merz Pharmaceuticals, LLC | 4 | $98 |
| Rayner Intraocular Lenses Limited | 5 | $90 |
| Rxsight Inc | 4 | $84 |
| Aerie Pharmaceuticals, Inc. | 4 | $82 |
| Glaukos Corporation | 4 | $73 |
| Eyevance Pharmaceuticals LLC | 3 | $55 |
| Iridex Corporation | 2 | $41 |
| Thea Pharma Inc. | 1 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Tearlab Corp | 1 | $18 |
| Dutch Ophthalmic, USA | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$17,450
- XIIDRA$12,980
- CEQUA$12,806
- Oxervate$2,750
- ARTEVO 800$1,546
- CIRRUS HD-OCT$1,546
- IOLMaster 700$1,546
- VERACITY SURGICAL$1,546
- VisuMax$1,546
- Tecnis 1-piece IOL$1,314
- Tecnis Multifocal Family of 1-piece IOLS$1,314
- Tecnis Symfony IOL$1,314
- EYSUVIS$1,300
- Prokera$1,177
- AmnioGraft$1,177
- Tecnis IOL$323
- MIEBO$290
- TRYPTYR$236
- VYZULTA$174
- LOTEMAX SM$170
How this compares
$61,703 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 16 | $450,588 |
| RestasisCyclosporine | 201 | $276,344 |
| XiidraLifitegrast | 127 | $193,307 |
| CequaCyclosporine | 135 | $126,317 |
| MieboPerfluorohexyloctane/Pf | 99 | $107,351 |
| LumiganBimatoprost | 86 | $59,554 |
| Cyclosporine | 42 | $25,779 |
| VevyeCyclosporine | 23 | $19,365 |
| Prednisolone Acetate | 295 | $13,164 |
| TyrvayaVarenicline Tartrate | 18 | $11,747 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $9,082 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $7,682 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $7,462 |
| Travoprost | 38 | $5,649 |
| Diclofenac Sodium | 363 | $4,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $3,324 | $450,58816 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,131 | $343,581306 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $731 | $300,658226 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $13,596 | $126,317135 claims |
| Harrow Eye, LLCVevye | $597 | $19,36523 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $603 | $11,74718 claims |
| AlconSimbrinza | $856 | $9,08225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Orlando
- Matthew CunninghamOrlando$2.9M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.